Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$12.63 - $24.47 $98,627 - $191,086
-7,809 Reduced 42.04%
10,767 $254,000
Q3 2023

Nov 13, 2023

BUY
$10.86 - $17.62 $201,735 - $327,309
18,576 New
18,576 $276,000
Q2 2022

Aug 15, 2022

BUY
$1.72 - $3.39 $29,893 - $58,918
17,380 Added 101.15%
34,563 $102,000
Q1 2022

May 13, 2022

BUY
$2.77 - $3.64 $47,596 - $62,546
17,183 New
17,183 $53,000
Q3 2021

Nov 12, 2021

SELL
$3.47 - $4.42 $116,793 - $148,768
-33,658 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$3.94 - $4.92 $56,267 - $70,262
14,281 Added 73.7%
33,658 $147,000
Q1 2021

May 14, 2021

BUY
$4.23 - $6.55 $81,964 - $126,919
19,377 New
19,377 $88,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.